In the lung, PDE5 is the PDE dominating cGMP-hydrolysis, and enhancing vascular cGMP by the pharmacological inhibition of PDE5 has been proved to be an effective treatment for pulmonary hypertension, similarly to the activation of NO-GC (16). This evidence concerns the gene PDE5A and pulmonary hypertension.